Corlanor
Drug
Amgen Inc.
Total Payments
$7.2M
Transactions
143,134
Doctors
18,242
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $96.61 | 2 | 2 |
| 2022 | $53,252 | 178 | 156 |
| 2021 | $78,217 | 1,990 | 1,187 |
| 2020 | $460,829 | 15,812 | 6,166 |
| 2019 | $2.4M | 38,126 | 9,912 |
| 2018 | $2.1M | 34,479 | 9,457 |
| 2017 | $2.1M | 52,547 | 12,230 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.1M | 64 | 57.2% |
| Food and Beverage | $2.3M | 142,526 | 31.5% |
| Space rental or facility fees (teaching hospital only) | $488,749 | 385 | 6.8% |
| Consulting Fee | $182,280 | 32 | 2.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $130,800 | 51 | 1.8% |
| Travel and Lodging | $14,906 | 67 | 0.2% |
| Education | $268.54 | 9 | 0.0% |
Payments by Type
Research
$4.1M
64 transactions
General
$3.1M
143,070 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure (PRIME-HF) | Amgen Inc. | $2.6M | 0 |
| P4-AA Heart Failure Registry | Amgen Inc. | $414,857 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Ivabradine Initiated at the Time of Discharge from the Observation Unit (OBSERVE-IVA) | Amgen Inc. | $293,048 | 0 |
| Relation of Heart Rate to Clinical Outcomes in a Large National Cohort of Veterans with Heart Failu | Amgen Inc. | $264,538 | 0 |
| Effect of Ivabradine on Patients with Postural orthostatic tachycardia syndrome | Amgen Inc. | $146,885 | 0 |
| Importance of heart rate as a prognostic marker in a pediatric population with dilated cardiomyopat | Amgen Inc. | $133,544 | 0 |
| Ivabradine in the management of cardiac autonomic dysfunction associated with thoracic radiation therapy | Amgen Inc. | $129,581 | 0 |
| Molecular and structural therapeutic phenotypes of heart rate lowering in heart failure with reduced left ventricular ejection fraction (HFrEF) | Amgen Inc. | $96,144 | 0 |
| Corlanor EHR Analysis | Amgen Inc. | $37,536 | 0 |
| Genetics of Heart Rate Observational Study GenHROuS | Amgen Inc. | $33,000 | 0 |
| Risk Factors for Hospitalization among Heart Failure Patients in Medicare data | Amgen Inc. | $20,700 | 0 |
| Ivabradine for Rate Control in Atrial Fibrillation | Amgen Inc. | $1,845 | 0 |
| Elevated Heart Rate and Rehospitalization: A Retrospective Medical Record Review of Patients with S | Amgen Inc. | $1,666 | 2 |
| Serial Assessment of Heart Rate and Beta Blocker Use in Chronic Heart Failure Patient with Reduced Rejection Fraction in a Large Integrated Healthcare Network | Amgen Inc. | $1,434 | 0 |
Top Doctors Receiving Payments for Corlanor — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Cardiovascular Disease | Meadville, PA | $2,787 | 29 |
| Richard Collins | — | Littleton, CO | $2,717 | 6 |
| , M.D | Interventional Cardiology | Los Alamitos, CA | $2,688 | 8 |
| , MD | Internal Medicine | Greensboro, NC | $2,685 | 40 |
| , M.D | Cardiovascular Disease | Scottsdale, AZ | $2,569 | 6 |
| , MD | Interventional Cardiology | Lodi, CA | $2,528 | 8 |
| , MD | Cardiovascular Disease | Houma, LA | $2,512 | 14 |
| , M.D | Internal Medicine | San Francisco, CA | $2,451 | 4 |
| , MD | Cardiovascular Disease | Chicago, IL | $2,441 | 2 |
| , MD | Cardiovascular Disease | Hollywood, FL | $2,419 | 13 |
| , M.D | Cardiovascular Disease | Boston, MA | $2,400 | 2 |
| , MD | Cardiovascular Disease | Dallas, TX | $2,380 | 1 |
| , MD | Internal Medicine | Schaumburg, IL | $2,302 | 9 |
| , M.D., M.P.H | Clinical Cardiac Electrophysiology | Imperial, CA | $2,231 | 2 |
| , MD | Cardiovascular Disease | Springfield, MO | $2,221 | 4 |
| , MD | Cardiovascular Disease | Boston, MA | $2,200 | 1 |
| Mohammad Shoukfeh | — | Lubbock, TX | $2,139 | 21 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Jackson, MS | $2,091 | 23 |
| , D.O | Cardiovascular Disease | Waterbury, CT | $2,080 | 15 |
| , MD | Cardiovascular Disease | Cleveland, OH | $2,000 | 1 |
| , MD | Cardiovascular Disease | Los Angeles, CA | $1,925 | 2 |
| , MD | Cardiovascular Disease | Amherst, NY | $1,903 | 12 |
| , M.D | Internal Medicine | Houston, TX | $1,901 | 8 |
| , M.D | Cardiovascular Disease | Lincoln, NE | $1,898 | 7 |
| , M.D | Cardiovascular Disease | New Britain, CT | $1,800 | 1 |
Ad
Manufacturing Companies
- Amgen Inc. $7.2M
Product Information
- Type Drug
- Total Payments $7.2M
- Total Doctors 18,242
- Transactions 143,134
About Corlanor
Corlanor is a drug associated with $7.2M in payments to 18,242 healthcare providers, recorded across 143,134 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2023. In 2023, $96.61 was paid across 2 transactions to 2 doctors.
The most common payment nature for Corlanor is "Unspecified" ($4.1M, 57.2% of total).
Corlanor is associated with 14 research studies, including "PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure (PRIME-HF)" ($2.6M).